ORTHOCON Announces Uninterrupted Availability of HEMASORB Resorbable Hemostatic Bone Putty

IRVINGTON, N.Y., Aug. 23, 2012 /PRNewswire/ -- On August 21, 2012, the U.S. Food and Drug Administration (FDA) announced that a hemostatic bone putty has been subjected to a Class 1 recall because of potential ignition if contacted with electrosurgical cautery systems under certain conditions during surgery. ORTHOCON and its hemostatic bone putty (HEMASORB) are not associated with this recall.

For more information regarding HEMASORB, please visit www.orthocon.com or call 914.357.2612.

 

SOURCE ORTHOCON

Suggested Articles

With generics at the gates, Novartis’ Gilenya secured a breath of fresh air—and protection for its blockbuster sales—with a federal injunction.

Akorn has been slammed with another FDA warning letter even as it is in the process of renegotiating its loans with lenders.

Horizon Therapeutics is preparing for the potential launch of inflammatory eye drug teprotumumab with team building.